Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms

Treitler, Peter; Bowden, Cadence F.; Lloyd, James F.; Enich, Michael; Nyaku, Amesika; Crystal, Stephen

doi:10.1016/j.jsat.2021.108514

Cited by 48 publications

(91 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings contrast with more than a few provider-based studies in which providers reported implementing federal policies to enhance MOUD access during COVID. Trietler et al’s study among a small group of New Jersey MOUD providers reported a shift towards telehealth, a reduction in toxicology screening and counseling services, and modifications to multi-day dosing [ 38 ]. A study of a San Francisco methadone treatment program reported full implementation of federal regulations (largely undefined) with outcomes demonstrating the benefit of increased take-home doses on hospitalizations and emergency department visits [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

“…telehealth, a reduction in toxicology screening and counseling services, and modifications to multi-day dosing [38]. A study of a San Francisco methadone treatment program reported full implementation of federal regulations (largely undefined) with outcomes demonstrating the benefit of increased take-home doses on hospitalizations and emergency department visits [39].…”

Section: Plos Onementioning

confidence: 99%

See 1 more Smart Citation

Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID

Meyerson

Bentele²,

Russell³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

Objective To understand patient experience of federal regulatory changes governing methadone and buprenorphine (MOUD) access in Arizona during the COVID-19 pandemic. Methods This community-based participatory and action research study involved one-hour, audio-recorded field interviews conducted with 131 people who used methadone and/or buprenorphine to address opioid use disorder at some point during COVID (January 1, 2020- March 31, 2021) in Arizona. Transcribed data were analyzed using a priori codes focused on federally recommended flexibilities governing MOUD access. Data were quantitated to investigate associations with COVID risk and services access. Results Telehealth was reported by 71.0% of participants, but the majority were required to come to the clinic to attend video appointments with an offsite provider. Risk for severe COVID outcomes was reported by 40.5% of the sample. Thirty-eight percent of the sample and 39.7% of methadone patients were required to be at the clinic daily to get medication and 47.6% were at high risk for COVID severe outcomes. About half (54.2%) of methadone patients indicated that some form of multi-day take home dosing was offered at their clinic, and 45.8% were offered an extra day or two of multi-day doses; but no participants received the federally allowed 14- or 28-day methadone take-home doses for unstable and stable patients respectively. All participants expressed that daily clinic visits interrupted their work and home lives and desired more take-home dosing and home delivery options. Conclusions MOUD patients in Arizona were not offered many of the federally allowed flexibilities for access that were designed to reduce their need to be at the clinic. To understand the impact of these recommended treatment changes in Arizona, and other states where they were not well implemented, federal and state regulators must mandate these changes and support MOUD providers to implement them.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Plos Onementioning

confidence: 99%

Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID

Meyerson

Bentele²,

Russell³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Priority in the resilience of national health insurance in addition to finance is a quality problem, which can reduce mortality. However, administratively the claim verification system still has problems in the process of disbursing claims for reimbursement for COVID-19 services at this time (Treitler et al, 2022).…”

Section: Claim Disputementioning

confidence: 99%

Claim Analysis of Cost Reimbursement COVID-19 Patient Service to Badan Penyelenggara Jaminan Sosial (BPJS) in health by Hospital

Sugiarto

Ilyas

2022

J. Sci. n.a

View full text Add to dashboard Cite

The BPJS COVID-19 fee claim is the government's support in accelerating the handling of COVID-19 in Indonesia. BPJS Health data from January to October 2021, the submission of claims for COVID-19 reached 1,345,970 cases with a cost value of 72.3 trillion IDR. Of the claims submitted by the hospital, only 79.07% were following BPJS claim verification or equivalent to 64.1 trillion IDR. There are still 21% of COVID-19 cost claims that require clarification on dispute resolution. Therefore, it is necessary to study the COVID-19 cost claim according to the provisions and find out the obstacles that occur in submitting BPJS claims by hospitals. The method used is descriptive-analytic by using literature searches, reading materials, and scientific journals. The results obtained are that the claim for COVID-19 costs uses the provisions of the tariff per day/cost per day which is regulated in the technical instructions for claiming reimbursement of costs for COVID-19 patient services number HK.01.07/MENKES/5673/2021. The conclusion obtained is that there are still problems with COVID-19 cost claims in the administrative aspect, the limitations of the verifier team, and the integration of the claim submission system.

show abstract

“…Interestingly, methadone and buprenorphine, along with counseling and psychosocial services offered by MAT programs, aim to the high adherence of patients to treatment. In parallel, this MAT practice intends to reduce illegal substance use and overdose mortality rates, as well as to inhibit aggressive and drug-seeking behaviors (Joseph et al, 2021;Treitler et al, 2022). Notwithstanding, because of the loosening of the regulations on MOUD attributed to COVID-19 measures, concerns regarding the diversion of opioids into the black market and the potential surge of harmful health consequences from misuse and overdose of prescribed medications have emerged (Del Pozo & Rich, 2020; Nagelhout et al, 2017; Nunes et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

“…signi cantly affect their lives through intensifying medical and psychiatric co-morbidity (Volkow, 2020;Williams et al, 2021). This global public health crisis has induced serious changes in the implemented programs of medication-assisted treatment (MAT), since it led to crucial modi cations in the delivery of medical care and in the regimen (i.e., management and administration) of medication for opioid use disorders (MOUD) (Chan et al, 2022;Treitler et al, 2022). In particular, there has been observed a trend by the OUDs patients to offer and buy illicit substances from black market (Baillargeon et al, 2021), thus altering the management of MOUD with craving and misuse being the most serious outcomes (Lambert, 2020).…”

mentioning

confidence: 99%

The development and validation of the pandemic medication-assisted treatment questionnaire for the assessment of the impact of pandemic crises on medication management and administration for patients with opioid use disorders

Leventelis

Katsouli

Stavropoulos

et al. 2022

Preprint

View full text Add to dashboard Cite

COVID-19 pandemic and the globally applied restriction measures mainly affect vulnerable population groups, such as patients with opioid use disorders. Towards inhibiting SARS-COV-2 spread, the medication-assisted treatment (MAT) programs follow strategies targeting reduction of in-person psychosocial interventions, and increase of take-home doses. However, there is no available instrument to examine the impact of such modifications on diverse health aspects of patients under MAT. The aim of this study was to develop and validate the PANdemic Medication-Assisted Treatment Questionnaire (PANMAT/Q) to address the pandemic effect on the management and administration of MAT. In total, 463 patients under ΜΑΤ participated. Our findings indicate that PANMAT/Q has been successfully validated exerting reliability and validity. It can be completed within approximately 5 minutes, and its implementation in research settings is advocated. PANMAT/Q could serve as a useful tool to identify the needs of patients under MAT being in high risk for relapse and overdose.

show abstract

Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms

Cited by 48 publications

References 34 publications

Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID

Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID

Claim Analysis of Cost Reimbursement COVID-19 Patient Service to Badan Penyelenggara Jaminan Sosial (BPJS) in health by Hospital

The development and validation of the pandemic medication-assisted treatment questionnaire for the assessment of the impact of pandemic crises on medication management and administration for patients with opioid use disorders

Contact Info

Product

Resources

About